Clinical trial · Interventional
Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain
NCT03317613CI-TRIAL-00056406CAPSONCOcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the oncology area, neuropathic pains are relatively frequent and can be induced by surgery, radiotherapy, or chemotherapy. In usual practice, some units are using qutenza in order to reduce neuropathic pain even though using of this patch for a population of cancer patients has never been demonstrated so far in a prospective study. The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuropathic Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Qutenza | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Capsaicin
- description
- Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..
- interventionNames
- Drug: Qutenza
Primary outcomes (1)
- measure
- Percentage of responders to capsaicin
- timeFrame
- One month
- description
- Percentage of responders to capsaicin at one month after the first patch application will be calculated with a relief scale completed by patients.
Secondary outcomes (10)
- measure
- Maximum value of relief
- timeFrame
- Three months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with at least 18 years old; * Patient presenting neuropathic pain secondary to an anti-cancerous treatment; * Patient presenting a DN4 (Neuropathic Pain in Four Questions) score superior or equal to 4 out of 10 * Patient presenting a skin without lesion at the painful area * Informed consent form signed; * Patient affiliated to a social security scheme. Exclusion Criteria: * Hypersensitivity known to capsaicin; * Instable or uncontrolled hypertension; * Painful area localised next to eyes; * Pregnant or breastfeeding woman; * Protected people.
References
Publications (0)
Data not yet available
No reference posted for this study.